ASCO Connection

September 2017

Issue link: http://read.uberflip.com/i/869954

Contents of this Issue

Navigation

Page 1 of 67

Visit AZimmuno-oncology.com to For locally advanced NSCLC PROGRESSION LIES AHEAD FOR MOST PATIENTS Up to 89% of patients with locally advanced NSCLC who benefit from chemoradiation therapy will advance to metastatic disease. 1

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO Connection - September 2017